Pharmacokinetics of doxorubicin co-administered with high-dose verapamil.

The potential for the modification of the pharmacokinetics of doxorubicin (DOX) concurrently administered with high-dose verapamil (VER) has been investigated in 17 patients with advanced neoplasms refractory to drugs belonging to the multidrug resistance spectrum. Steady-state concentration of DOX,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gigante, M., Toffoli, G., Boiocchi, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033454/
https://www.ncbi.nlm.nih.gov/pubmed/7819028
_version_ 1782136841289334784
author Gigante, M.
Toffoli, G.
Boiocchi, M.
author_facet Gigante, M.
Toffoli, G.
Boiocchi, M.
author_sort Gigante, M.
collection PubMed
description The potential for the modification of the pharmacokinetics of doxorubicin (DOX) concurrently administered with high-dose verapamil (VER) has been investigated in 17 patients with advanced neoplasms refractory to drugs belonging to the multidrug resistance spectrum. Steady-state concentration of DOX, systemic clearance and urinary excretion were analysed. No significant difference was found between the kinetic parameters estimated for DOX at different levels of VER and those reported for doxorubicin as single agent. It can be concluded that VER does not appear to modify DOX kinetics.
format Text
id pubmed-2033454
institution National Center for Biotechnology Information
language English
publishDate 1995
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20334542009-09-10 Pharmacokinetics of doxorubicin co-administered with high-dose verapamil. Gigante, M. Toffoli, G. Boiocchi, M. Br J Cancer Research Article The potential for the modification of the pharmacokinetics of doxorubicin (DOX) concurrently administered with high-dose verapamil (VER) has been investigated in 17 patients with advanced neoplasms refractory to drugs belonging to the multidrug resistance spectrum. Steady-state concentration of DOX, systemic clearance and urinary excretion were analysed. No significant difference was found between the kinetic parameters estimated for DOX at different levels of VER and those reported for doxorubicin as single agent. It can be concluded that VER does not appear to modify DOX kinetics. Nature Publishing Group 1995-01 /pmc/articles/PMC2033454/ /pubmed/7819028 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Gigante, M.
Toffoli, G.
Boiocchi, M.
Pharmacokinetics of doxorubicin co-administered with high-dose verapamil.
title Pharmacokinetics of doxorubicin co-administered with high-dose verapamil.
title_full Pharmacokinetics of doxorubicin co-administered with high-dose verapamil.
title_fullStr Pharmacokinetics of doxorubicin co-administered with high-dose verapamil.
title_full_unstemmed Pharmacokinetics of doxorubicin co-administered with high-dose verapamil.
title_short Pharmacokinetics of doxorubicin co-administered with high-dose verapamil.
title_sort pharmacokinetics of doxorubicin co-administered with high-dose verapamil.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033454/
https://www.ncbi.nlm.nih.gov/pubmed/7819028
work_keys_str_mv AT gigantem pharmacokineticsofdoxorubicincoadministeredwithhighdoseverapamil
AT toffolig pharmacokineticsofdoxorubicincoadministeredwithhighdoseverapamil
AT boiocchim pharmacokineticsofdoxorubicincoadministeredwithhighdoseverapamil

Ejemplares similares